Wyeth Pharmaceuticals has awarded $4 million to the National Comprehensive Cancer Network to conduct studies investigating the effectiveness of temsirolimus in treating solid tumors. Temsirolimus is the active agent in Torisel, Wyeth's treatment for advanced renal cell carcinoma. The trials also aim to identify biomarkers and molecular imaging methods for inhibiting the mammalian target of rapamycin signaling pathway that controls tumor development.

Related Summaries